(Q38932495)

7 September 2017

Antibody targeting of HER2/HER3 signaling overcomes heregulin-induced resistance to PI3K inhibition in prostate cancer (English)

1 reference

7 September 2017

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25471734%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

E. Sally Ward

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25471734%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

author name string

Jayakumar S Poovassery

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25471734%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Jeffrey C Kang

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25471734%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Dongyoung Kim

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25471734%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

language of work or name

English

0 references

publication date

19 December 2014

1 reference

International Journal of Cancer

7 September 2017

11

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25471734%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

volume

137

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25471734%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25471734%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

page(s)

267-277

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25471734%20AND%20SRC:MED&resulttype=core&format=json

Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths

10 June 2020

cites work

1 reference

Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world

21 January 2018

1 reference

Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion

21 January 2018

1 reference

The development of androgen-independent prostate cancer

21 January 2018

1 reference

A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase.

21 January 2018

1 reference

Targeting ErbB3: the New RTK(id) on the Prostate Cancer Block

21 January 2018

1 reference

Untangling the ErbB signalling network

21 January 2018

1 reference

The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis

21 January 2018

1 reference

Novel anticancer targets: revisiting ERBB2 and discovering ERBB3.

21 January 2018

1 reference

Therapeutically targeting ErbB3: a key node in ligand-induced activation of the ErbB receptor-PI3K axis.

21 January 2018

1 reference

21 January 2018

Neuregulins and cancer.

1 reference

Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3.

21 January 2018

1 reference

Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors.

21 January 2018

1 reference

Molecular pathways: HER3 targeted therapy

21 January 2018

1 reference

Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway

21 January 2018

1 reference

Predictive value of PTEN and AR coexpression of sustained responsiveness to hormonal therapy in prostate cancer--a pilot study.

21 January 2018

1 reference

Integrative genomic profiling of human prostate cancer

21 January 2018

1 reference

The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer

21 January 2018

1 reference

NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.

21 January 2018

1 reference

AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity

21 January 2018

1 reference

Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer

21 January 2018

1 reference

Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer.

21 January 2018

1 reference

A potential autocrine loop between heregulin-alpha and erbB-3 receptor in human prostatic adenocarcinoma

21 January 2018

1 reference

Engineering multivalent antibodies to target heregulin-induced HER3 signaling in breast cancer cells

21 January 2018

1 reference

Analyses of the recycling receptor, FcRn, in live cells reveal novel pathways for lysosomal delivery.

21 January 2018

1 reference

Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941

21 January 2018

1 reference

Loss of PTEN permits CXCR4-mediated tumorigenesis through ERK1/2 in prostate cancer cells

21 January 2018

1 reference

Dual EGFR/HER2 inhibition sensitizes prostate cancer cells to androgen withdrawal by suppressing ErbB3

21 January 2018

1 reference

Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941

21 January 2018

1 reference

Humanization of an anti-p185HER2 antibody for human cancer therapy

21 January 2018

1 reference

Targeting of distinct signaling cascades and cancer-associated fibroblasts define the efficacy of Sorafenib against prostate cancer cells

21 January 2018

1 reference

A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis

21 January 2018

1 reference

Dasatinib inhibits site-specific tyrosine phosphorylation of androgen receptor by Ack1 and Src kinases

21 January 2018

1 reference

Neuregulin promotes autophagic cell death of prostate cancer cells

21 January 2018

1 reference

Neuregulin-induced ErbB3 downregulation is mediated by a protein stability cascade involving the E3 ubiquitin ligase Nrdp1

21 January 2018

1 reference

Alternative intracellular routing of ErbB receptors may determine signaling potency

21 January 2018

1 reference

Monoclonal antibody-induced ErbB3 receptor internalization and degradation inhibits growth and migration of human melanoma cells.

21 January 2018

1 reference

Regression of human prostate cancer xenografts in mice by AMG 212/BAY2010112, a novel PSMA/CD3-Bispecific BiTE antibody cross-reactive with non-human primate antigens.

21 January 2018

1 reference

Antibody-drug conjugates targeting prostate-specific membrane antigen

21 January 2018

1 reference

Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: critical role for neuregulin blockade in antitumor response to combination therapy.

21 January 2018

1 reference

Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity

21 January 2018

1 reference

The ERBB3 receptor in cancer and cancer gene therapy

21 January 2018

1 reference

HER2 overcomes PTEN (loss)-induced senescence to cause aggressive prostate cancer

21 January 2018

1 reference